How much is the sclerotherapy market worth?

In 2027 the market for sclerotherapy is valued at USD 1.35 billion.

How is the sclerotherapy industry projected to perform over the next decade?

Sclerotherapy Market size was estimated at USD 1.3 billion in 2026 and is projected to grow at a 4.18% CAGR from 2027 to 2036, exceeding USD 1.96 billion by 2036.

How is rising prevalence of venous disorders influencing demand for minimally invasive sclerotherapy treatments?

Increasing cases of varicose veins, spider veins, and chronic venous insufficiency are expanding patient inflow to vascular and dermatology clinics. Sclerotherapy benefits from outpatient delivery and lower invasiveness, driving higher procedure volumes and earlier adoption in treatment pathways.

How are foam and ultrasound-guided advancements improving adoption in the sclerotherapy market?

Foam formulations and ultrasound-guided delivery improve targeting of less visible veins and enhance procedural accuracy. This expands treatable cases, increases physician confidence, and supports broader integration of sclerotherapy through improved outcomes and reduced administration variability.

Why are detergents the leading agents segment in the sclerotherapy market?

Detergents captured 46.11% of the market in 2026 due to broad clinical familiarity, routine use, and consistent integration into established sclerotherapy workflows that support dependable procedural outcomes.

Why is ultrasound sclerotherapy the fastest-growing treatment type?

Ultrasound Sclerotherapy is expanding rapidly as providers increasingly rely on imaging guidance for more precise vein localization and injection accuracy, supporting greater confidence during treatment procedures.

What makes North America the leading regional market for sclerotherapy?

North America held a 47.17% share in 2026, supported by established outpatient care, broad access to vein treatment services, experienced providers, and consistent demand for minimally invasive procedures.

Why is the Asia Pacific sclerotherapy market growing steadily?

Asia Pacific is projected to expand at a 5.13% CAGR as access to aesthetic and vein care services improves, clinic capacity increases, and more patients seek minimally invasive treatment options.

What are the key competitors in the sclerotherapy landscape?

Leading players in the sclerotherapy market include Merz Pharma GmbH & Co. KGaA (Germany), Viatris Inc. (United States), Perrigo Company plc (Ireland), Troikaa Pharmaceuticals Ltd. (India), LGM Pharma (United States), Chemische Fabrik Kreussler & Co. GmbH (Germany), AngioDynamics, Inc. (United States).